Cambridge's Agios wins FDA approval for second cancer drug

"This is a shift in the entire treatment paradigm," Agios CEO David Schenkein told the Business Journal. "This is obviously a very exciting day for Agios, but even more so, for patients who now have a treatment that wasn't previously available."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.